References
- Prakash A, Benfield P. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 1998;55:145–63.
- CPMP/EWP.239/95 Final. Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents.
- EU Guideline. Clinical Investigation on Corticosteroids intended for use on the skin. Directive 75/318/EEC February 1987.
- Questions and Answers on Guideline. Clinical investigation of corticosteroids intended for use on the skin. DHPM/EWP/21441/2006, adopted on 16 Nov 2006.
- FDA Guidance for Industry. Topical dermatologic corticosteroids: in vivo bioequivalence, 2 June 1995.
- McKenzie AW, Stoughton RΒ. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962;86:608.
- Tsai JC, Cheng CL, Tsai YF, et al. Evaluation of in vivo bioequivalence methodology for topical clobetasol 17-propionate based on pharmacodynamic modeling using Chinese skin. J Pharm Sci 2004;93:207–17.
- Au WL, Skinner M, Kanfer I. Bioequivalence assessment of topical clobetasol propionate products using visual and chromametric assessment of skin blanching. J Pharm Pharm Sci 2008;11:160–6.
- Pershing LK, Silver BS, Krueger GG, et al. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a blanching bioassay. Pharm Res 1992;9:45–51.
- Barry BW, Woodford R. Activity and bioavailability of topical corticosteroids: In vivo/in vitro correlations for the vasoconstrictor test. J Clin Pharmacol 1978;3:43–65.
- Burdick KH. Corticosteroid bioavailability assays. Correlation with a clinical study. Acta Derm Venereol Suppl (Stockh) 1972;52:19–23.
- Coleman GL, Kanfer I, Haigh JM. Comparative blanching activities of proprietary diflucortolone valerate topical preparations. Dermatologica 1978;156:224–30.
- Meyer E, Magnus AD, Haigh JM, Kanfer I. Comparison of the blanching activities of Dermovate, Betnovate and Eumovate creams and ointments. Int J Pharm 1988;41:63–6.
- Keida T, Hayashi N, Kawashima M. Application of the Food and Drug Administration (FDA) bioequivalent guidance of topical dermatological corticosteroid in yellow-skinned Japanese population: validation study using a chromameter. J Dermatol 2006;10:684–91.
- Pershing LK, Lambert LD, Shah VP, Lam SY. Variability and correlation of chromameter and tape-stripping methods with the visual skin blanching assay in the quantitative assessment of topical 0.05% betamethasone dipropionate bioavailability in humans. Int J Pharm 1992;86:201–10.
- Schwarb FP, Smith EW, Haigh JM, Surber C. Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data. Eur J Pharm Biopharm 1999;47:261–7.
- Au WL, Skinner M, Kanfer I. Comparison of tape stripping with the human skin blanching assay for the bioequivalence assessment of topical clobetasol propionate formulations. J Pharm Pharmaceut Sci 2010;13:11–20.
- Grieve KA, Barnes TM. Bioequivalence of 0.1% mometasone furoate lotion to 0.1% mometasone furoate hydrogel. Australias J Dermatol 2016;57:e39–45.